Sciwind Biosciences Announces Ecnoglutide Injection Approved by China's National Medical Products Administration (NMPA) for Chronic Weight Management
HANGZHOU, China, March 6, 2026 /PRNewswire/ -- Hangzhou Sciwind Biosciences Co., Ltd. ("Sciwind"), a biopharmaceutical company focused on the discovery and development of innovative therapies for metabolic diseases, announced today that China's...
Jaypirca® (Pirtobrutinib) Approved in China for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
SAN FRANCISCO and SUZHOU, China, March 2, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of...
Basecare Medical (HK.2170) Receives NMPA Approval for Core Product Geri Medium, Unlocking New Opportunities in Assisted Reproduction
SUZHOU, China, Feb. 27, 2026 /PRNewswire/ -- Basecare Medical (02170.HK) has recently encountered a key catalyst——its Gems one-step embryo culture medium has officially obtained the China Class III Medical Device Registration Certificate (National...
DIFF Biotech's Innovative Nasal Spray Influenza Vaccine Receives Clinical Trial Approval, Introducing a New Attenuation Pathway
HANGZHOU, China, Feb. 9, 2026 /PRNewswire/ -- Zhejiang Difference Biological Technology Co., Ltd. (DIFF Biotech) announced that its proprietary nasal spray influenza attenuated live vaccine, DIFF-flu, has recently received clinical trial approval as...
Sciwind Biosciences Announces Ecnoglutide Injection Approved by China's National Medical Products Administration (NMPA) for Adult Type 2 Diabetes
HANGZHOU, China, Jan. 30, 2026 /PRNewswire/ -- Sciwind Biosciences Co., Ltd. ("Sciwind"), a biopharmaceutical company focused on the discovery and development of innovative therapies for metabolic diseases, announced today that China's National...